The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
MASTER KEY project: A basket/umbrella trial for rare cancers in Japan.
 
Hitomi Sumiyoshi Okuma
No Relationships to Disclose
 
Kan Yonemori
Honoraria - Eisai; Novartis; Taiho Pharmaceutical
 
Toshio Shimizu
Honoraria - Boehringer Ingelheim; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
Speakers' Bureau - Boehringer Ingelheim; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - 3D Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Five Prime Therapeutics; PharmaMar; Takeda/Millennium
 
Yasushi Goto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Pfizer; Shionogi; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; Kyorin; Lilly; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie; Lilly Japan; Pfizer
 
Yoshitaka Honma
Speakers' Bureau - Bayer; Bristol-Myers Squibb Japan; Merck Serono; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Teijin Pharma
Research Funding - AstraZeneca; Daiichi Sankyo; Merck Serono; Novelpharm; Teijin Pharma
 
Chigusa Morizane
Honoraria - Fujifilm; Lilly; Nobelpharma; Novartis; Pfizer; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Novartis; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Eisai (Inst); Nobelpharma (Inst); ONO PHARMACEUTICAL (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Emi Noguchi
No Relationships to Disclose
 
Kazuki Sudo
Honoraria - Bristol-Myers Squibb Japan; Taiho Pharmaceutical
 
Wataru Munakata
Honoraria - Chugai Pharma; Eisai; Ono Pharmaceutical
 
Kuniko Sunami
No Relationships to Disclose
 
Nobuyoshi Hiraoka
No Relationships to Disclose
 
Takashi Kohno
Research Funding - Daiichi Sankyo; Sysmex
 
Akihiro Hirakawa
Consulting or Advisory Role - Abbvie; Astellas Pharma; Nippon Boehringer Ingelheim; Nippon Shinyaku; Ono Pharmaceutical
Speakers' Bureau - Pfizer
 
Taro Shibata
No Relationships to Disclose
 
Tamie Sukigara
No Relationships to Disclose
 
Akira Kawai
Honoraria - Eisai; Lilly; Novartis; Taiho Pharmaceutical; Takara Bio
Consulting or Advisory Role - Ignyta; Lilly; Novartis; Taiho Pharmaceutical
 
Noboru Yamamoto
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Boehringer Ingelheim; Eisai; OncoTherapy Science; Otsuka; Takeda
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kenichi Nakamura
Honoraria - Eisai; Merck Serono; Nihonkayaku; Taiho Pharmaceutical
 
Toshirou Nishida
Honoraria - Bayer; Novartis; Pfizer; Sysmex; Tsumura & Co.
 
Yasuhiro Fujiwara
Honoraria - AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo; Novartis; Taiho Pharmaceutical